We came across a bullish thesis on Stryker Corporation (SYK) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on SYK.

Stryker Corporation (SYK)’s share was trading at $353.42 as of April 14th. SYK’s trailing and forward P/E were 45.54 and 26.04 respectively according to Yahoo Finance.

PBH currently has a forward P/E ratio of 16.76, while SYK has a forward P/E of 25.04. We also note that PBH has a PEG ratio of 2.39. This metric is used similarly to the famous P/E ratio, but the ...

Below is Validea's guru fundamental report for STRYKER CORP (SYK). Of the 22 guru strategies we follow, SYK rates highest using our P/B Growth Investor model based on the published strategy of ...

Though oftentimes over-the-top and surface level in its critique, “Syk Pike” is nevertheless a witty examination of narcissism, unabashedly holding up a mirror to humanity’s worst tendencies.

The agreement will see Bischofberger’s Kronos Bio buy Gilead’s portfolio of spleen tyrosine kinase (SYK) inhibitors and vault into clinical development. In 2010, ...

Spleen tyrosine kinase (SYK) is known to have a crucial role in adaptive immune receptor signalling. However, recent reports indicate that SYK also mediates other, unexpectedly diverse biological ...

The protein kinase Syk is a key mediator of proximal B-cell receptor (BCR) signaling. Following antigen stimulation, Syk is recruited to the BCR and becomes activated by phosphorylation at Y352.